Vikas Sinha
Equibles does not estimate personal net worth.
About Vikas Sinha
Vikas Sinha is recorded as CEO at Kalaris Therapeutics, Inc. (KLRS) since December 19, 2024. Kalaris Therapeutics, Inc. reported in an 8-K filed March 18, 2025 that Vikas Sinha resigned as President. Kalaris Therapeutics, Inc. reported in an 8-K filed March 18, 2025 that Vikas Sinha resigned as Chief Financial Officer. Kalaris Therapeutics, Inc. reported in an 8-K filed March 18, 2025 that Vikas Sinha resigned as principal accounting officer. Equibles holds 7 filed executive changes naming Vikas Sinha; each is listed under recent activity with its source filing. The proxy statement of Kalaris Therapeutics, Inc. reports total compensation of $1,100,954 for Vikas Sinha in fiscal 2025, including a base salary of $81,106. Disclosed compensation is on record for 7 fiscal years. Kalaris Therapeutics, Inc. is classified in the Biotechnology industry within the Healthcare sector. Other leadership on record at Kalaris Therapeutics, Inc. includes Andrew Oxtoby (CEO and Board Member), Diana M. Brainard (CEO and Board Member), David Hallal (Chairman and Board Member) and 7 others.
“Vikas Sinha resigned as AlloVir's Chief Executive Officer, President, Chief Financial Officer, principal executive officer, principal financial officer and principal accounting officer”
“Vikas Sinha resigned as AlloVir's Chief Executive Officer, President, Chief Financial Officer, principal executive officer, principal financial officer and principal accounting officer”
Affiliation history
-
Current
2024-12-19–present
-
2024-12-19–2025-03-18
-
Start not stated–2025-03-18
Company network
Leadership on record at Kalaris Therapeutics, Inc.
- Andrew Oxtoby CEO, Board Member
- Diana M. Brainard CEO, Board Member
- David Hallal Chairman, Board Member
- Brett Hagen CFO
- Liisa Bayko CFO
- Matthew Gall CFO
- Amy Vandekop Chief Accounting Officer
- Anthony Adamis Board Member
- Derek Adams, Ph.D. Board Member
- Laurie Keating Board Member
Executive compensation
Compensation components disclosed in company proxy statements. Amounts are nominal USD; total is the company-reported figure.
| Fiscal year | Company | Role | Salary | Total |
|---|---|---|---|---|
| 2025 | Kalaris Therapeutics, Inc. (KLRS) | AlloVir’s Former Chief Executive Officer, President and Chief Financial Officer | $81,106 | $1,100,954 |
| 2024 | Kalaris Therapeutics, Inc. (KLRS) | AlloVir’s Former Chief Executive Officer, President and Chief Financial Officer | $375,448 | $544,400 |
| 2023 | Kalaris Therapeutics, Inc. (KLRS) | AlloVir’s Former Chief Executive Officer, President and Chief Financial Officer | $373,042 | $2,940,669 |
| 2022 | Kalaris Therapeutics, Inc. (KLRS) | President and Chief Financial Officer | $369,007 | $2,904,162 |
| 2021 | Kalaris Therapeutics, Inc. (KLRS) | President and Chief Financial Officer | $425,000 | $6,622,996 |
| 2020 | Kalaris Therapeutics, Inc. (KLRS) | President and Chief Financial Officer | $412,000 | $6,320,540 |
| 2019 | Kalaris Therapeutics, Inc. (KLRS) | President and ChiefFinancial Officer | $400,000 | $1,629,646 |